$CLYM

2021 Q3 Form 10-Q Financial Statement

#000095017021001783 Filed on September 13, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.394M $2.914M $1.537M
YoY Change 987.82% 1065.6%
% of Gross Profit
Research & Development $5.704M $5.478M $13.57M
YoY Change 195.54% 313.43%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $9.383M $8.707M $15.11M
YoY Change 315.36% 441.48%
Operating Profit -$9.383M -$8.707M
YoY Change 315.36% 441.48%
Interest Expense -$252.0K -$12.00K $244.0K
YoY Change -25300.0% -40.0%
% of Operating Profit
Other Income/Expense, Net -$232.0K -$12.00K $0.00
YoY Change -23300.0% -47.83%
Pretax Income -$9.615M -$8.719M -$14.86M
YoY Change 325.82% 434.91%
Income Tax
% Of Pretax Income
Net Earnings -$9.615M -$8.719M -$14.86M
YoY Change 325.82% 434.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.70 -$3.11
Diluted Earnings Per Share -$616.9K -$3.11 -$586.1K
COMMON SHARES
Basic Shares Outstanding 26.55M 3.488M
Diluted Shares Outstanding 15.59M 3.488M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $146.0M $99.48M
YoY Change
Cash & Equivalents $62.82M $99.48M $20.49M
Short-Term Investments $83.20M
Other Short-Term Assets $12.61M $5.321M
YoY Change
Inventory
Prepaid Expenses $1.960M $0.00
Receivables
Other Receivables
Total Short-Term Assets $158.6M $104.8M $22.00M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $2.824M $2.633M
YoY Change
Total Long-Term Assets $23.62M $2.824M $2.633M
YoY Change
TOTAL ASSETS
Total Short-Term Assets $158.6M $104.8M $22.00M
Total Long-Term Assets $23.62M $2.824M $2.633M
Total Assets $182.3M $107.6M $24.63M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.579M $1.955M $1.086M
YoY Change
Accrued Expenses $2.979M $3.631M $1.219M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.590M $5.713M $3.063M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.590M $5.713M $3.063M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.590M $5.713M $3.063M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$65.10M -$55.50M -$28.14M
YoY Change
Common Stock $241.8M $4.611M $3.153M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $176.7M -$50.85M -$24.98M
YoY Change
Total Liabilities & Shareholders Equity $182.3M $107.6M $24.63M
YoY Change

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q4
OPERATING ACTIVITIES
Net Income -$9.615M -$8.719M -$14.86M
YoY Change 325.82% 434.58%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$12.97M -$8.481M -$5.624M
YoY Change 110.88% 125.56%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$106.9M $8.078M
YoY Change
Cash From Investing Activities -$106.9M $8.078M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 83.14M 59.97M 4.925M
YoY Change
NET CHANGE
Cash From Operating Activities -12.97M -8.481M -5.624M
Cash From Investing Activities -106.9M 8.078M
Cash From Financing Activities 83.14M 59.97M 4.925M
Net Change In Cash -36.74M 51.49M 7.379M
YoY Change 497.53% -1469.31%
FREE CASH FLOW
Cash From Operating Activities -$12.97M -$8.481M -$5.624M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Shell Company
EntityShellCompany
false
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
3226000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
891000
elym Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
-62000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
166000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
110000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
9375
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
1.86
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
59466
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
150000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
us-gaap Preferred Stock Redemption Date
PreferredStockRedemptionDate
2026-10-31
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001768446
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40708
dei Entity Registrant Name
EntityRegistrantName
ELIEM THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2273741
dei Entity Address Address Line1
EntityAddressAddressLine1
23515 NE Novelty Hill Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B221 #125
dei Entity Address City Or Town
EntityAddressCityOrTown
Redmond
dei Entity Address State Or Province
EntityAddressStateOrProvince
WA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
98053
dei City Area Code
CityAreaCode
425
dei Local Phone Number
LocalPhoneNumber
276-2300
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ELYM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26547901
CY2021Q2 us-gaap Cash
Cash
99482000
CY2020Q4 us-gaap Cash
Cash
20487000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5321000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1511000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
104803000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
21998000
CY2021Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
2824000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
2633000
CY2021Q2 us-gaap Assets
Assets
107627000
CY2020Q4 us-gaap Assets
Assets
24631000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1955000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1086000
CY2021Q2 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
0
CY2020Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
207000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3631000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1219000
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
127000
CY2020Q4 us-gaap Accounts Payable And Accrued Liabilities Fair Value Disclosure
AccountsPayableAndAccruedLiabilitiesFairValueDisclosure
0
CY2021Q2 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
0
CY2020Q4 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
551000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
5713000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3063000
CY2021Q2 us-gaap Liabilities
Liabilities
5713000
CY2020Q4 us-gaap Liabilities
Liabilities
3063000
CY2021Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15345286
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12909389
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15345279
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15345279
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7140157
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7140157
CY2021Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
147096000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
49891000
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
152759000
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
46551000
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
46000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3489956
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3489956
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3418751
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3418751
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2021Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
4610000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
3152000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55456000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-28136000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-50845000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-24983000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
107627000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
24631000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5478000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1325000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9751000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2714000
CY2021Q2 elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
315000
CY2020Q2 elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
35000
elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
703000
elym Research And Development Expense Related Parties
ResearchAndDevelopmentExpenseRelatedParties
269000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2914000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
248000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5132000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
576000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
8707000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
1608000
us-gaap Operating Expenses
OperatingExpenses
15586000
us-gaap Operating Expenses
OperatingExpenses
3559000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-8707000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1608000
us-gaap Operating Income Loss
OperatingIncomeLoss
-15586000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3559000
CY2021Q2 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2020Q2 elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-12000
CY2020Q2 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-23000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-16000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
12000
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11734000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8719000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1631000
us-gaap Net Income Loss
NetIncomeLoss
-27320000
us-gaap Net Income Loss
NetIncomeLoss
-3547000
CY2021Q2 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
2141000
CY2020Q2 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
452000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10860000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2083000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30546000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4438000
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.11
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.39
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3488017
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1859703
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3472086
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1857617
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-24983000
CY2021Q1 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
105000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
297000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-18601000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-43182000
CY2021Q2 elym Exercise Of Stock Options And Release Of Restricted Stock Awards
ExerciseOfStockOptionsAndReleaseOfRestrictedStockAwards
6000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1050000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-8719000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-50845000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-5562000
CY2020Q1 elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
-439000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
134000
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-1916000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-7783000
CY2020Q2 elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
-452000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
-0
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
51000
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-1631000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-9815000
us-gaap Profit Loss
ProfitLoss
-27320000
us-gaap Profit Loss
ProfitLoss
-3547000
us-gaap Share Based Compensation
ShareBasedCompensation
1347000
us-gaap Share Based Compensation
ShareBasedCompensation
185000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
166000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
110000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
3810000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
1824000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
192000
elym Increase Decrease In Non Current Assets
IncreaseDecreaseInNonCurrentAssets
735000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
871000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-381000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2411000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
381000
elym Increase Decrease In Accounts Payable And Accrued Liabilities Related Party
IncreaseDecreaseInAccountsPayableAndAccruedLiabilitiesRelatedParty
-80000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15221000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6093000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
93939000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
111000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94050000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
78995000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-5983000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20487000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21223000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
99482000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15240000
elym Temporary Equity Accretion Reduction To Redemption Value
TemporaryEquityAccretionReductionToRedemptionValue
891000
us-gaap Nature Of Operations
NatureOfOperations
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Organization</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Eliem Therapeutics, Inc. (the Company) is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Headquartered in Redmond, Washington, the Company was incorporated on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 18, 2018</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> as a Delaware corporation.</span></p>
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-10-18
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55500000
CY2021Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
15345286
CY2020Q4 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
627000
CY2021Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1018000
CY2020Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
592000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the interim condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures. Accordingly, actual results could differ from those estimates. Key management estimates include those related to the valuation of assets acquired, accrual of research and development expenses, the valuation of stock-based awards, the valuation of common stock and redeemable convertible preferred stock, and the valuation of redeemable convertible preferred stock tranche liabilities. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash. The Company’s cash is held by one financial institution in the United States (U.S.) and one financial institution in the United Kingdom (U.K.). The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s deposits held in the U.S. and U.K. may exceed the Federal Depository Insurance Corporation and Financial Services Compensation Scheme, respectively, insured limits.</span></p>
CY2021Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
575000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
0
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3631000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1219000
CY2020Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
551000
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1000000.0
CY2021Q2 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
2541000
CY2020Q4 elym Recoverable Research And Development Tax Credits
RecoverableResearchAndDevelopmentTaxCredits
0
CY2021Q2 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1282000
CY2020Q4 elym Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
1500000
CY2021Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1040000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
0
CY2021Q2 us-gaap Other Assets
OtherAssets
458000
CY2020Q4 us-gaap Other Assets
OtherAssets
11000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5321000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1511000
CY2021Q2 elym Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2038000
CY2021Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
15345279
CY2021Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
15345279
CY2021Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
152759000
CY2021Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
147096000
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
12909389
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7140157
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
7140157
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
46551000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
49891000
elym Cumulative Dividends Receive
CumulativeDividendsReceive
0.08
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0
CY2020Q4 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
551000
elym Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiability
11718000
elym Reclassification Of Redeemable Convertible Preferred Stock Tranche Liability Upon Settlement
ReclassificationOfRedeemableConvertiblePreferredStockTrancheLiabilityUponSettlement
-12269000
CY2021Q2 elym Redeemable Convertible Preferred Stock Tranche Liability
RedeemableConvertiblePreferredStockTrancheLiability
0
CY2021Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
14000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
12000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
28000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
25000
CY2021Q2 us-gaap Operating Leases Future Minimum Payments Due Future Minimum Sublease Rentals
OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals
700000
us-gaap Lease Expiration Date1
LeaseExpirationDate1
2023-06-30
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
435342
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.52
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2641893
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.35
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M8D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
415000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2275392
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1050000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
51000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1347000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
185000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
9200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y5M4D
elym Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
P9Y6M21D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
23482000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2641893
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.35
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P9Y6M21D
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
23482000
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
182013
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y7M13D
CY2021Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2013000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.44
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7881
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7917
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0094
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0113
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
21747
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-8719000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1631000
us-gaap Net Income Loss
NetIncomeLoss
-27320000
us-gaap Net Income Loss
NetIncomeLoss
-3547000
CY2021Q2 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
2141000
CY2020Q2 elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
452000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
3226000
elym Accretion Of Redeemable Convertible Preferred Stock To Redemption Value And Cumulative Preferred Stock Dividends
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueAndCumulativePreferredStockDividends
891000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10860000
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2083000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-30546000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4438000
CY2021Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3488017
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1859703
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3472086
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1857617
CY2021Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.11
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.12
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-8.80
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.39
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18339838
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18339838
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4487360
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4487360
CY2021Q3 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
1-for-1
CY2021Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
300000
CY2020Q2 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
100000
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
700000
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
300000

Files In Submission

Name View Source Status
0000950170-21-001783-index-headers.html Edgar Link pending
0000950170-21-001783-index.html Edgar Link pending
0000950170-21-001783.txt Edgar Link pending
0000950170-21-001783-xbrl.zip Edgar Link pending
elym-20210630.htm Edgar Link pending
elym-20210630.xsd Edgar Link pending
elym-20210630ex31_1.htm Edgar Link pending
elym-20210630ex31_2.htm Edgar Link pending
elym-20210630ex32_1.htm Edgar Link pending
elym-20210630ex32_2.htm Edgar Link pending
elym-20210630_cal.xml Edgar Link unprocessable
elym-20210630_def.xml Edgar Link unprocessable
elym-20210630_htm.xml Edgar Link completed
elym-20210630_lab.xml Edgar Link unprocessable
elym-20210630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img155832562_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending